Background-It is unclear whether intravenous glycoprotein IIb/IIIa inhibitors or ischemic time might modify any clinical benefits observed with aspiration thrombectomy before primary percutaneous coronary intervention (PCI) in patients with ST-segment-elevation myocardial infarction. Methods and Results-Electronic databases were searched for trials that randomized ST-segment-elevation myocardial infarction patients to aspiration thrombectomy before PCI versus conventional PCI. Summary estimates were constructed using a DerSimonian-Laird model. Seventeen trials with 20 960 patients were available for analysis. When compared with conventional PCI, aspiration thrombectomy was not associated with a significant reduction in the risk of mortality 2.8% versus 3.2% (risk ratio [RR], 0.89; 95% confidence interval [CI], 0.76-1.04; P=0.13), reinfarction 1.3% versus 1.4% (RR, 0.93; 95% CI, 0.73-1.17; P=0.52), the combined outcome of mortality or reinfarction 4.1% versus 4.6% (RR, 0.90; 95% CI, 0.79-1.02; P=0.11), or stent thrombosis 0.9% versus 1.2% (RR, 0.82; 95% CI, 0.62-1.08; P=0.15). Aspiration thrombectomy was associated with a nonsignificant increase in the risk of stroke 0.6% versus 0.4% (RR, 1.45; 95% CI, 0.96-2.21; P=0.08). Meta-regression analysis did not identify a difference for the log RR of mortality, reinfarction, and the combined outcome of mortality or reinfarction with intravenous glycoprotein IIb/IIIa inhibitors (P=0.17, 0.70, and 0.50, respectively) or with ischemic time (P=0.29, 0.66, and 0.58, respectively). Conclusions-Aspiration thrombectomy before primary PCI is not associated with any benefit on clinical end points and might increase the risk of stroke. Concomitant administration of intravenous glycoprotein IIb/IIIa inhibitors and ischemic time did not seem to influence any potential benefits observed with aspiration thrombectomy. (Circ Cardiovasc Interv. 2015;8:e002258.
S uboptimal coronary reperfusion in patients with
ST-segment-elevation myocardial infarction (STEMI) is associated with worse outcomes. 1, 2 Aspiration thrombectomy has been available as an adjunctive therapy to aid in the restoration of coronary blood flow at the epicardial and microvascular levels. An earlier meta-analysis had suggested that aspiration thrombectomy at the time of primary percutaneous coronary intervention (PCI) was associated with better outcomes 3 ; however, recent randomized trials demonstrated the lack of clinical benefits with routine aspiration thrombectomy. 4, 5 Furthermore, some studies suggested that this adjunctive technology might be associated with an increased risk of stroke. 3, 4, 6 Earlier studies suggested that intravenous glycoprotein IIb/IIIa inhibitors administration was associated with improved outcomes in STEMI patients undergoing primary PCI. 7 However, studies conducted in the current era of potent ADP antagonists demonstrated lack of clear clinical outcome benefit with glycoprotein IIb/IIIa inhibitors usage. [8] [9] [10] A previous retrospective study had suggested that the combination of intravenous glycoprotein IIb/IIIa inhibitors with adjunctive aspiration thrombectomy had better clinical outcomes than either treatment modality separately. 11 In the randomized trials evaluating clinical outcomes with aspiration thrombectomy, the usage of glycoprotein IIb/IIIa inhibitors has been variable which could have modified any association between aspiration thrombectomy and adverse cardiovascular outcomes. 4, 5, [12] [13] [14] In addition, in these trials there was variation in ischemic time, which might also affect any clinical benefit from aspiration thrombectomy. 15, 16 In this study, we aimed to conduct a comprehensive metaanalysis to evaluate the outcomes associated with aspiration thrombectomy with the totality of data. Moreover, we sought to explore the effect of coadministration of intravenous glycoprotein IIb/IIIa inhibitors as well as ischemic time on any Outcomes With Aspiration Thrombectomy potential benefits observed with aspiration thrombectomy in STEMI patients undergoing primary PCI.
Methods

Data Sources
A computerized search of the Medline, Web of Science, and the Cochrane databases was conducted without language restriction from inception until April 2015 using the Medical Subject Heading and the key word search terms illustrated in Figure I in the Data Supplement. To ensure that no potentially important studies were missed, the reference lists from the retrieved articles and prior meta-analyses were also checked. 3, [17] [18] [19] [20] [21] We communicated with select authors when further article clarification was necessary.
Selection Criteria
We selected trials that randomized patients presenting with STEMI within 12 hours of symptom onset to aspiration thrombectomy before PCI versus conventional PCI. Eligible trials were published studies that reported clinical outcome data. Because we planned to explore the effects of glycoprotein IIb/IIIa inhibitors as an effect modifier, we required that the trials reported the percentage of glycoprotein IIb/IIIa inhibitors usage even if the reported percentage of glycoprotein IIb/ IIIa inhibitors usage was zero.
Outcomes and Definitions
The outcomes that were assessed in this analysis included all-cause mortality, reinfarction, the combined outcome of mortality or reinfarction, major adverse cardiac events (MACEs), stent thrombosis, stroke, and myocardial reperfusion markers (ie, complete ST-segment resolution, and Thrombolysis In Myocardial Infarction (TIMI) blush grade). If the study did not specifically report a definition for MACE, we defined it as the composite of all-cause mortality, reinfarction, or urgent target vessel revascularization. If the individual study reported outcomes at variable follow-up duration, we used the earliest reported follow-up to maximize homogeneity among follow-up duration. Studies that reported outcomes at hospital discharge were assumed to have a follow-up duration of 3 days.
Statistical Analysis
This analysis was conducted in concordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. 22 We tabulated the number of events that occurred in the treatment arms of each study. Random effects summary risk ratio (RR) were constructed using a DerSimonian-Laird model. 23 If there were zero events in a treatment arm, 0.5 was added to each cell. A study with zero events in both treatment arms was excluded. Statistical heterogeneity was assessed for each outcome using the I 2 statistic. I 2 statistic values <25%, 25% to 50%, and >50% were considered as low, moderate, and high degree of heterogeneity, respectively. 24 To account for the possibility of a variable treatment effect with a longer follow-up time, a planned subgroup analysis for all-cause mortality was conducted for the trials that reported mortality at both 1 and 12 months. Random effects metaregression for the logarithm for RR for each outcome and the average percentage of glycoprotein IIb/IIIa inhibitors usage between both arms, as well as ischemic time, were constructed. 25 A study with zero events in a treatment arm was excluded from meta-regression. All P values were 2-tailed, with statistical significance set at 0.05. The statistical analysis was performed using STATA software version 11 (STATA Corporation; College Station, TX).
Results
Included Studies
Seventeen trials with 20 960 patients were available for the analysis. 4, 5, [12] [13] [14] [15] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] The weighted mean follow-up duration was 3.7±2.7 months. Three trials reported outcomes at both 1 and 12 months. 5, 12, 14, [38] [39] [40] The mean time between the onset of symptoms to primary PCI was similar in both groups (4.5±1.5 hours; P=0.86). Five trials defined MACE as the composite of death, reinfarction, stroke, or target vessel revascularization. 12, [32] [33] [34] 37 MACE was defined in 5 studies as death, reinfarction, or target vessel revascularization. 14, 15, 26, 27, 31 In 1 study, death, reinfarction, or stroke was used as the MACE definition, 36 whereas another study used death, reinfarction, or hospitalization for heart failure as the MACE definition. 35 Another study defined MACE as composite of death from cardiovascular causes, reinfarction, cardiogenic shock, or New York Heart Association class IV heart failure. 4 The remaining 4 studies did not specifically define MACE. 5, [28] [29] [30] All the studies that reported complete ST-segment resolution used the cutoff ≥70%, 4,12-14,26,28-31,34-37 except for 1 study that used ≥50%. 32 Seven studies defined successful reperfusion as TIMI blush grade of 3, 13, 14, 26, 29, 32, 34, 35 whereas 5 studies used TIMI blush grade of ≥2. 12, 28, 30, 31, 37 In Table 1 , we summarize the baseline characteristics, the primary outcome, and the follow-up duration of the included studies, whereas Table 2 reports the study medications.
Outcomes
The incidence of all-cause mortality was 2.8% with aspiration thrombectomy versus 3.2% with conventional PCI (RR, 0.89; 95% confidence interval [CI], 0.76-1.04; P=0.13; I 2 =0%). On subgroup analysis, the risk of all-cause mortality was similar at 1 month (RR, 0.86; 95% CI, 0.61-1.20; P=0.36) and at 12 months (RR, 0.82; 95% CI, 0.61-1.09; P=0.17). The incidence
WHAT IS KNOWN
• The use of adjunctive aspiration thrombectomy at the time of primary percutaneous coronary intervention is associated with improved myocardial reperfusion; however, recent trials have demonstrated lack of clinical benefit.
• Intravenous glycoprotein IIb/IIIa inhibitors are potent antiplatelet agents that have been shown to reduce the risk of ischemic events in patients undergoing primary percutaneous coronary intervention.
• It remains unclear whether coadministration of intravenous glycoprotein IIb/IIIa inhibitors, ischemic time, or other factors might modify any clinical benefits of aspiration thrombectomy.
WHAT THE STUDY ADDS
• Aspiration thrombectomy does not reduce the risk of all-cause mortality, reinfarction, the combined outcome of mortality or reinfarction, major adverse cardiac events, or stent thrombosis when compared with conventional percutaneous coronary intervention. Aspiration thrombectomy might be associated with an increased risk of stroke.
• Concomitant administration of intravenous glycoprotein IIb/IIIa inhibitors at the time of primary percutaneous coronary intervention or ischemic time does not seem to enhance any potential clinical benefits observed with aspiration thrombectomy. of reinfarction was 1.3% with aspiration thrombectomy versus 1.4% with conventional PCI (RR, 0.93; 95% CI, 0.73-1.17; P=0.52; I 2 =0%). The incidence of the combined outcome of mortality or reinfarction was 4.1% with aspiration thrombectomy versus 4.6% with conventional PCI (RR, 0.90; 95% CI, 0.79-1.02; P=0.11; I 2 =0%). The incidence of MACE was 6.0% with aspiration thrombectomy versus 6.6% with conventional PCI (RR, 0.90; 95% CI, 0.81-1.00; P=0.06; I 2 =0%). Figure 1 shows the forest plot for all-cause mortality, reinfarction, the combined outcome of mortality or reinfarction, and MACE. The incidence of stent thrombosis was 0.9% with aspiration thrombectomy versus 1.2% with conventional PCI (RR, 0.82; 95% CI, 0.62-1.08; P=0.15; I 2 =0%; Figure II in the Data Supplement). Aspiration thrombectomy was associated with a nonsignificant increase in the risk of stroke 0.6% versus 0.4% (RR, 1.45; 95% CI, 0.96-2.21; P=0.08; I 2 =0%; Figure III in the Data Supplement). Aspiration thrombectomy was associated with a higher incidence of complete ST-segment resolution 68% versus 64% (RR, 1.17; 95% CI, 1.08-1.28; P<0.0001; I 2 =66%), and improved myocardial blush grade of ≥2 59% versus 43% (RR, 1.39; 95% CI, 1.19-1.62; P<0.0001; I 2 =84%).
Meta-Regression
Meta-regression analysis did not identify a difference for the log RR of all-cause mortality, reinfarction, the combined outcome of mortality or reinfarction, MACE, complete STsegment resolution, or TIMI blush grade of ≥2 with the percentage of the glycoprotein IIb/IIIa inhibitors usage (P=0.17, 0.70, 0.58, 0.77, 0.17, and 0.98, respectively). Figures 2 and 3 demonstrate the meta-regression plot for mortality and the combined outcome of mortality or reinfarction with the percentage of the glycoprotein IIb/IIIa inhibitors usage. Figures IV and V in the Data Supplement demonstrate the meta-regression plot for the reinfarction and MACE with the percentage of the glycoprotein IIb/IIIa inhibitors usage. We were not able to conduct a separate meta-regression analysis using the difference in the percentage of glycoprotein IIb/IIIa inhibitors between treatment arms because only 3 trials exhibited a modest difference in the percentage of glycoprotein IIb/IIIa inhibitors usage between arms. 26, 32, 33 Similarly, meta-regression analysis did not identify a difference for the log RR of all-cause mortality, reinfarction, the combined outcome of mortality or reinfarction, MACE, complete ST-segment resolution, and TIMI blush grade of ≥2 because of limited studies available for analysis (several studies were excluded with zero events in a single arm). A separate meta-regression for second generation drug-eluting stents with the individual outcomes also could not be performed because of the limited number of studies reporting this information.
Discussion
In this analysis of 17 randomized trials, we demonstrated that aspiration thrombectomy did not significantly reduce the risk of all-cause mortality, reinfarction, the combined outcome of mortality or reinfarction, MACE, or stent thrombosis when compared with conventional PCI. In addition, aspiration thrombectomy was associated with a nonsignificant increase in the risk of stroke. Moreover, the concomitant administration of intravenous glycoprotein IIb/IIIa inhibitors or ischemic time did not influence (ie, reduce) the risk of mortality, reinfarction, the combined outcomes of mortality or reinfarction, MACE, or myocardial reperfusion markers in STEMI patients who underwent aspiration thrombectomy before primary PCI.
We performed a meta-regression to examine the relationship 41 In the majority of the included studies, patients were pretreated with ADP antagonists and in particular clopidogrel. Our findings were limited to intravenous administration of abciximab, except for the Infuse-Acute Myocardial Infarction (INFUSE-AMI) trial, in which abciximab was administered via an intralesional route by perfusion balloon.
Prior randomized trials and meta-analyses had shown disparate results for the short-term benefits of aspiration thrombectomy [3] [4] [5] [17] [18] [19] [20] [21] ; however, none of the studies was designed to address the potential synergistic effect of glycoprotein IIb/IIIa inhibitors on outcomes. In the INFUSE-AMI trial, patients were randomized in a 2×2 factorial design to intralesional abciximab at the site of the infarct lesion using a special infusion catheter versus no intracoronary abciximab. Patients were also simultaneously randomized to aspiration thrombectomy versus no aspiration thrombectomy. Major adverse cardiac and cerebrovascular events at 1 year were numerically lowest (6.8%) in the group that received intralesional abciximab and thrombectomy, when compared with 8.5% with aspiration thrombectomy alone, 9.3% with intralesional abciximab alone, and 11.2% with neither; however, these differences did not achieve statistical significance (P=0.71). 39 A recent study demonstrated that concomitant use of glycoprotein IIb/IIIa inhibitors may have a synergistic effect with aspiration thrombectomy on 30-day mortality. 42 However, that analysis did not include the totality of data. Also, in our meta-regression analysis, we tested our hypothesis against various outcomes and we sought to eliminate potential bias by excluding studies that had zero events in a single arm. The overall results of this meta-analysis differ from prior meta-analyses likely because of the inclusion of a much larger number of patients and events, as well as a greater number of sites and operators, making the results more generalizable. It is not uncommon for initial favorable effects of experimental treatments to be overestimated. It is also possible that concurrent advances in doorto-balloon time and stent technology have reduced thrombotic complications of primary PCI. 
Outcomes With Aspiration Thrombectomy
Our study has some limitations. First, the primary outcome for the majority of the included studies was myocardial reperfusion markers and not clinical outcomes. Second, MACE was not uniformly defined among all the studies; however, we also observed no benefit in the outcome of mortality or myocardial infarction. Third, a few studies were excluded in the meta-regression because of no events. Fourth, benefits such as ability to perform direct stenting or reduced stent length were not examined, as we focused on clinical end points.
In conclusion, aspiration thrombectomy before primary PCI was not associated with any clinical benefit and might increase the risk of stroke. Moreover, the coadministration of intravenous glycoprotein IIb/IIIa inhibitors and ischemic time did not seem to influence any potential benefits observed with aspiration thrombectomy.
